PeterForsythMD

Neuro-Oncology

Physician

Overview of Dr. Forsyth

Dr. Peter Forsyth is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from Michael G. DeGroote School of Medicine and has been in practice 30 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 50 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 USF Magnolia Drive
Tampa, FL 33612
Book by Phone+1(484) 929-2876

Fax+1 813-449-8246

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1988 - 1991
Michael G. DeGroote School of MedicineClass of 1987

Certifications & Licensure

FL State Medical License 2011 - 2025
CT State Medical License 1993 - 1994
American Board of Psychiatry and Neurology Neurology

Clinical Trials

RO4929097 in Treating Patients With Recurrent Invasive Gliomas Start of enrollment: 2011 Jul 01
Terminated
Phase 1
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Start of enrollment: 2009 Oct 01
Unknown status
Phase 3
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Start of enrollment: 2019 Jun 10
Active, not recruiting
Phase 1
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Start of enrollment: 2019 Jul 30
Recruiting
Phase 2, Phase 3
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
Recruiting
Phase 1, Phase 2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Start of enrollment: 2021 Nov 30
Recruiting
Phase 1, Phase 2
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Start of enrollment: 2023 Jun 06
Active, not recruiting
Early Phase 1
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Start of enrollment: 2016 May 01
Recruiting
Phase 2
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Start of enrollment: 2023 Aug 22
Recruiting
Phase 1
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Start of enrollment: 2022 Dec 19
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

89 citations
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
Faith E. Davies, Peter D. Forsyth, Andy C. Rawstron, Roger G. Owen, Guy Pratt
British Journal of Haematology. 2001-03-01
824 citations
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, Alain Algazi, Omid Hamid, F. Stephen Hodi
The New England Journal of Medicine. 2018-08-22
122 citations
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label...
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, F. Stephen Hodi, Alain Algazi, Omid Hamid
The Lancet. Oncology. 2021-11-10

Press Mentions

Molecular Characteristics of Leptomeningeal Melanoma MetastasesJanuary 10th, 2020
Molecular Characteristics of Leptomeningeal Melanoma MetastasesJanuary 10th, 2020
Shop TalkOctober 20th, 2019
Join now to see all